ES / EN
- September 23, 2023 -
No Result
View All Result
OnCubaNews Needs You
OnCubaNews
  • World
  • Cuba
  • Cuba-USA
  • Opinion
    • Columns
    • Infographic
  • Culture
    • Billboard
  • Sports
  • Styles / Trends
  • Media
  • Special
  • Cuban Flavors
  • World
  • Cuba
  • Cuba-USA
  • Opinion
    • Columns
    • Infographic
  • Culture
    • Billboard
  • Sports
  • Styles / Trends
  • Media
  • Special
  • Cuban Flavors
OnCubaNews
ES / EN
Home Cuba

Cuba uses monoclonal antibody to control “cytokine storm” in COVID-19 patients

The drug, which is commonly used to treat other conditions such as psoriasis and rheumatoid arthritis, has been used in 70 patients from nine hospitals on the island.

by EFE EFE, EFE EFE
May 14, 2020
in Cuba
0
The Cuban drug Itolizumab used in the treatment of COVID-19. Photo: Courtesy of CIM/Granma.

The Cuban drug Itolizumab used in the treatment of COVID-19. Photo: Courtesy of CIM/Granma.

Cuba is using the humanized monoclonal antibody Itolizumab within the COVID-19 protocol for patients’ medical care to stop the so-called “cytokine storm,” an uncontrolled reaction of the immune system that can have fatal consequences.

The drug, which is commonly used to treat other conditions such as psoriasis and rheumatoid arthritis, has been used in 70 patients from nine Cuban hospitals, the director of Clinical Investigations of Cuba’s Molecular Immunology Center (CIM), Tania Crombet, affirmed to the daily Granma.

“It has been used in patients classified as critical, serious and care, with a high risk of aggravation. The best results have been seen in critically and seriously ill patients,” assured the doctor.

Scientific studies have linked this “cytokine storm” with hyper inflammation and the appearance of acute respiratory failure syndrome or adult respiratory distress syndrome (ARDS), which has been described as the leading cause of COVID-19 mortality.

The director of Clinical Investigations of the CIM, belonging to the BioCubaFarma Business Group, explained in the interview that the drug “can reduce the secretion of a group of mediators of the inflammation, known as pro-inflammatory cytokines.”

This, according to the specialist, would ultimately allow “stopping in time” the consequences of the cytokine storm, a potentially deadly defensive immune reaction.

Related Posts

Cubans in line at the Havana airport. Migration in Cuba

Crisis, expectations and migration in Cuba

September 16, 2023
Photo: Kaloian.

Where are we and what else to do to start picking up the economy?

September 14, 2023
Andorra, town without cane. Photo: Jorge Ricardo.

Andorra, town without sugarcane

September 12, 2023
Inauguration of the Mundo Virtual. Photo: Ricardo López Hevia.

Cuba: the game is about electronic sports

September 11, 2023

Coronavirus: Más de cinco mil personas tratadas en Cuba con la Biomodulina T

“Itolizumab works in the phase of the disease where the damage is caused by the exaggerated response of the immune system to the enormous capacity of the virus to divide,” said the specialist.

She also assured that there are “clinical and imaging evidence of improvement of respiratory distress” in patients.

Dr. Crombet clarified that her team is immersed “in the data collection and interpretation stage, in order to draw definitive conclusions.”

Itolizumab, produced in Cuba since 2014, obtained that same year one of the National Awards of the Cuban Academy of Sciences, and in 2015 it was recognized with the Gold Medal of the World Intellectual Property Organization (WIPO), according to Granma.

The company Biocon is also developing and producing this drug in India, where it is mainly used to treat psoriasis patients, although its efficacy in combating coronavirus has also started being tested.

The coronavirus has so far left 1,804 infected in Cuba, 78 deceased and 1,277 recovered.

Authors

EFE EFE, EFE EFE
Tags: coronavirus in CubaCuban science
Previous Post

On nursing day, more than applause

Next Post

Speeding up of first Cuba-China biotech park project to produce medicines

EFE

EFE

EFE

EFE

Next Post
A worker produces artemisinin, a medicine to treat malaria, at a plant in Rongan County, Guangxi Zhuang Autonomous Region, China. Photo: Xinhua

Speeding up of first Cuba-China biotech park project to produce medicines

Cuba has processed a total of 75,142 tests, of which 1,830 have been positive. The death toll is 79. Photo: Otmaro Rodríguez.

This morning finds Cuba without deaths and with 20 cases of COVID-19

Photo: Flickr.

Study to detect positive cases in asymptomatic persons starts in Camagüey

Leave a Reply Cancel reply

The conversation here is moderated according to OnCuba News discussion guidelines. Please read the Comment Policy before joining the discussion.

Your email address will not be published. Required fields are marked *

Most Read

  • Cubans in line at the Havana airport. Migration in Cuba

    Crisis, expectations and migration in Cuba

    10 shares
    Share 4 Tweet 3
  • Lessons to Learn From How Cubans Became Republicans

    332 shares
    Share 132 Tweet 83
  • The salmon flight. From Brooklyn to Cayo Hueso without regrets

    6 shares
    Share 2 Tweet 2
  • Marylin Monroe and Afro-Americans

    81 shares
    Share 32 Tweet 20
  • Biden administration could announce measures to provide “greater financial support” to SMEs in Cuba

    5 shares
    Share 2 Tweet 1

Most Commented

    • About us
    • Work with OnCuba
    • Terms of use
    • Privacy Policy
    • Moderation policy for comments
    • Contact us
    • Advertisement offers

    OnCuba and the OnCuba logo are registered® trademarks of Fuego Enterprises, Inc., its subsidiaries or divisions.
    OnCuba © by Fuego Enterprises, Inc. All Rights Reserved.

    No Result
    View All Result
    • World
    • Cuba
    • Cuba-USA
    • Opinion
      • Columns
      • Infographic
    • Culture
      • Billboard
    • Sports
    • Styles / Trends
    • Media
    • Special
    • Cuban Flavors

    OnCuba and the OnCuba logo are registered® trademarks of Fuego Enterprises, Inc., its subsidiaries or divisions.
    OnCuba © by Fuego Enterprises, Inc. All Rights Reserved.

    Go to mobile version